Biocon shares slipped over 2 per cent on Thursday morning after the US health regulator issued six observations in Form 483 after pre-approval inspection of its insulin drug Substance Manufacturing Facility in Bengaluru. “The USFDA concluded a pre-approval inspection of Biocon’s insulin drug substance manufacturing facility triggered by a New Drug Application submitted by the company’s insulin API customer,” the company said.